Cargando…

Metabolomic biosignature differentiates melancholic depressive patients from healthy controls

BACKGROUND: Major depressive disorder (MDD) is a heterogeneous disease at the level of clinical symptoms, and this heterogeneity is likely reflected at the level of biology. Two clinical subtypes within MDD that have garnered interest are “melancholic depression” and “anxious depression”. Metabolomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yashu, Yieh, Lynn, Yang, Tao, Drinkenburg, Wilhelmus, Peeters, Pieter, Steckler, Thomas, Narayan, Vaibhav A., Wittenberg, Gayle, Ye, Jieping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994306/
https://www.ncbi.nlm.nih.gov/pubmed/27549765
http://dx.doi.org/10.1186/s12864-016-2953-2
_version_ 1782449302619029504
author Liu, Yashu
Yieh, Lynn
Yang, Tao
Drinkenburg, Wilhelmus
Peeters, Pieter
Steckler, Thomas
Narayan, Vaibhav A.
Wittenberg, Gayle
Ye, Jieping
author_facet Liu, Yashu
Yieh, Lynn
Yang, Tao
Drinkenburg, Wilhelmus
Peeters, Pieter
Steckler, Thomas
Narayan, Vaibhav A.
Wittenberg, Gayle
Ye, Jieping
author_sort Liu, Yashu
collection PubMed
description BACKGROUND: Major depressive disorder (MDD) is a heterogeneous disease at the level of clinical symptoms, and this heterogeneity is likely reflected at the level of biology. Two clinical subtypes within MDD that have garnered interest are “melancholic depression” and “anxious depression”. Metabolomics enables us to characterize hundreds of small molecules that comprise the metabolome, and recent work suggests the blood metabolome may be able to inform treatment decisions for MDD, however work is at an early stage. Here we examine a metabolomics data set to (1) test whether clinically homogenous MDD subtypes are also more biologically homogeneous, and hence more predictiable, (2) devise a robust machine learning framework that preserves biological meaning, and (3) describe the metabolomic biosignature for melancholic depression. RESULTS: With the proposed computational system we achieves around 80 % classification accuracy, sensitivity and specificity for melancholic depression, but only ~72 % for anxious depression or MDD, suggesting the blood metabolome contains more information about melancholic depression.. We develop an ensemble feature selection framework (EFSF) in which features are first clustered, and learning then takes place on the cluster centroids, retaining information about correlated features during the feature selection process rather than discarding them as most machine learning methods will do. Analysis of the most discriminative feature clusters revealed differences in metabolic classes such as amino acids and lipids as well as pathways studied extensively in MDD such as the activation of cortisol in chronic stress. CONCLUSIONS: We find the greater clinical homogeneity does indeed lead to better prediction based on biological measurements in the case of melancholic depression. Melancholic depression is shown to be associated with changes in amino acids, catecholamines, lipids, stress hormones, and immune-related metabolites. The proposed computational framework can be adapted to analyze data from many other biomedical applications where the data has similar characteristics. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12864-016-2953-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4994306
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49943062016-08-24 Metabolomic biosignature differentiates melancholic depressive patients from healthy controls Liu, Yashu Yieh, Lynn Yang, Tao Drinkenburg, Wilhelmus Peeters, Pieter Steckler, Thomas Narayan, Vaibhav A. Wittenberg, Gayle Ye, Jieping BMC Genomics Methodology Article BACKGROUND: Major depressive disorder (MDD) is a heterogeneous disease at the level of clinical symptoms, and this heterogeneity is likely reflected at the level of biology. Two clinical subtypes within MDD that have garnered interest are “melancholic depression” and “anxious depression”. Metabolomics enables us to characterize hundreds of small molecules that comprise the metabolome, and recent work suggests the blood metabolome may be able to inform treatment decisions for MDD, however work is at an early stage. Here we examine a metabolomics data set to (1) test whether clinically homogenous MDD subtypes are also more biologically homogeneous, and hence more predictiable, (2) devise a robust machine learning framework that preserves biological meaning, and (3) describe the metabolomic biosignature for melancholic depression. RESULTS: With the proposed computational system we achieves around 80 % classification accuracy, sensitivity and specificity for melancholic depression, but only ~72 % for anxious depression or MDD, suggesting the blood metabolome contains more information about melancholic depression.. We develop an ensemble feature selection framework (EFSF) in which features are first clustered, and learning then takes place on the cluster centroids, retaining information about correlated features during the feature selection process rather than discarding them as most machine learning methods will do. Analysis of the most discriminative feature clusters revealed differences in metabolic classes such as amino acids and lipids as well as pathways studied extensively in MDD such as the activation of cortisol in chronic stress. CONCLUSIONS: We find the greater clinical homogeneity does indeed lead to better prediction based on biological measurements in the case of melancholic depression. Melancholic depression is shown to be associated with changes in amino acids, catecholamines, lipids, stress hormones, and immune-related metabolites. The proposed computational framework can be adapted to analyze data from many other biomedical applications where the data has similar characteristics. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12864-016-2953-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-08-23 /pmc/articles/PMC4994306/ /pubmed/27549765 http://dx.doi.org/10.1186/s12864-016-2953-2 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Methodology Article
Liu, Yashu
Yieh, Lynn
Yang, Tao
Drinkenburg, Wilhelmus
Peeters, Pieter
Steckler, Thomas
Narayan, Vaibhav A.
Wittenberg, Gayle
Ye, Jieping
Metabolomic biosignature differentiates melancholic depressive patients from healthy controls
title Metabolomic biosignature differentiates melancholic depressive patients from healthy controls
title_full Metabolomic biosignature differentiates melancholic depressive patients from healthy controls
title_fullStr Metabolomic biosignature differentiates melancholic depressive patients from healthy controls
title_full_unstemmed Metabolomic biosignature differentiates melancholic depressive patients from healthy controls
title_short Metabolomic biosignature differentiates melancholic depressive patients from healthy controls
title_sort metabolomic biosignature differentiates melancholic depressive patients from healthy controls
topic Methodology Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994306/
https://www.ncbi.nlm.nih.gov/pubmed/27549765
http://dx.doi.org/10.1186/s12864-016-2953-2
work_keys_str_mv AT liuyashu metabolomicbiosignaturedifferentiatesmelancholicdepressivepatientsfromhealthycontrols
AT yiehlynn metabolomicbiosignaturedifferentiatesmelancholicdepressivepatientsfromhealthycontrols
AT yangtao metabolomicbiosignaturedifferentiatesmelancholicdepressivepatientsfromhealthycontrols
AT drinkenburgwilhelmus metabolomicbiosignaturedifferentiatesmelancholicdepressivepatientsfromhealthycontrols
AT peeterspieter metabolomicbiosignaturedifferentiatesmelancholicdepressivepatientsfromhealthycontrols
AT stecklerthomas metabolomicbiosignaturedifferentiatesmelancholicdepressivepatientsfromhealthycontrols
AT narayanvaibhava metabolomicbiosignaturedifferentiatesmelancholicdepressivepatientsfromhealthycontrols
AT wittenberggayle metabolomicbiosignaturedifferentiatesmelancholicdepressivepatientsfromhealthycontrols
AT yejieping metabolomicbiosignaturedifferentiatesmelancholicdepressivepatientsfromhealthycontrols